Company profile for Alys Pharmaceuticals

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Established in February 2024, Alys Pharmaceuticals emerges as a pioneering force in immuno-dermatology, a venture co-founded by Medixci in collaboration with renowned dermatology and scientific experts worldwide. Formed through the integration of six asset-centric Medixci companies, Alys proudly presents a formidable pipeline of inventive programs and platforms designed to address various dermatological conditions. Guided by a...
Established in February 2024, Alys Pharmaceuticals emerges as a pioneering force in immuno-dermatology, a venture co-founded by Medixci in collaboration with renowned dermatology and scientific experts worldwide. Formed through the integration of six asset-centric Medixci companies, Alys proudly presents a formidable pipeline of inventive programs and platforms designed to address various dermatological conditions. Guided by a vision to revolutionize the treatment landscape for prevalent dermatological indications characterized by substantial unmet medical needs, Alys aims to reshape the paradigm of dermatological treatments.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Boston Massachusetts 02210
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/alys-pharmaceuticals-doses-first-subject-in-phase-11b-trial-of-aly-301-a-first-in-class-mast-cell-selective-c-kit-inhibitor-for-chronic-urticaria-302598702.html

PR NEWSWIRE
30 Oct 2025

https://www.prnewswire.com/news-releases/alys-pharmaceuticals-announces-cta-submission-for-aly-301-the-first-mast-cell-selective-c-kit-inhibitor-for-treatment-of-cold-urticaria-302476572.html

PR NEWSWIRE
10 Jun 2025

https://www.prnewswire.com/news-releases/alys-pharmaceuticals-announces-dosing-of-first-patient-in-phase-iia-trial-of-aly-101-for-alopecia-areata-302412452.html

PR NEWSWIRE
27 Mar 2025

https://www.prnewswire.com/news-releases/alys-pharmaceuticals-receives-ind-clearance-for-phase-2a-trial-of-first-genetic-medicine-program-in-dermatology-302366489.html

PR NEWSWIRE
04 Feb 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty